Proceedings of Anticancer Research

Application of Proteomic and Metabolomic Technologies in Renal Cell Carcinoma and Research Progress of Related Biomarkers

2025-05-29T15:41:48+08:00

Renal cell carcinoma (RCC), which accounts for about 90 percent of kidney cancers, has a distinct metabolic reprogramming profile characterized by increased aerobic glycolysis (Warburg effect), abnormal accumulation of lipids, and impaired mitochondrial function. Recent advances in high-throughput proteomic and metabolomic technologies have revolutionized our understanding of the pathophysiology of RCC, allowing for the systematic identification of disease-specific molecular signatures, elucidation of drug resistance mechanisms, and possible targets for intervention. The review focuses on the use of proteomic and metabolomic technologies in renal cell carcinoma and the research progress on related biomarkers, and is expected to provide useful information for the early detection and treatment of RCC.

LINC00936 Suppresses Non-Small Cell Lung Cancer Progression Through Modulation of the Ras/MAPK Signaling Pathway

2025-05-29T15:41:50+08:00

Objective: To characterize the tumor-suppressive role of LINC00936 in non-small cell lung cancer (NSCLC) through mechanistic exploration of its regulatory pathways. Methods: Bioinformatics interrogation of TCGA/NSCLC cohorts assessed LINC00936 expression, clinical correlations, and immune contexture. Functional enrichment analyses predicted pathway associations. In H1299 cells, LINC00936 overexpression (plasmid) and knockdown (siRNA) models were validated by RT-qPCR. Transcriptomic profiling identified differentially expressed genes (DEGs) subjected to KEGG pathway analysis. Results: LINC00936 was significantly downregulated in NSCLC tissues (TCGA, P < 0.05) and cell lines (vs. 16-HBE, P < 0.05), correlating with poor prognosis and altered tumor-infiltrating immune subsets. DEG enrichment implicated Ras/MAPK signaling as the dominant pathway (FDR < 0.05). Successful LINC00936 modulation (overexpression/knockdown, P < 0.05) confirmed its regulatory capacity. Conclusion: LINC00936 acts as a tumor suppressor in NSCLC via Ras/MAPK pathway modulation, proposing its therapeutic candidacy for precision oncology strategies.

Risk Assessment Models for Venous Thromboembolism in Gynecological Patients: A Review of Current Practices and Future Directions

2025-05-29T15:41:46+08:00

This article introduces and compares risk assessment models for venous thromboembolism in gynecological patients at home and abroad. The models assessed included the Caprini risk assessment model, the G-Caprini risk assessment model, the Rogers risk assessment model, the Autar risk assessment model, the gynecological patient surgical venous thrombosis risk assessment scale, the Wells score, the COMPASS-CAT thrombus risk assessment model, the Khorana risk assessment model, the Padua risk assessment model, and the Chaoyang model. The purpose of this study is to provide a foundation for developing a risk assessment tool for gynecological venous thromboembolism tailored to Chinese patients and to assist clinical health care workers in selecting appropriate risk assessment tools and guiding individualized prevention measures.

Observation on the Effect of Interventional Therapy Combined with Lenvatinib and Sintilimab in the Treatment of Advanced Liver Cancer

2025-05-29T15:41:43+08:00

Objective: To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer. Methods: 82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups. Group A received interventional therapy combined with lenvatinib and sintilimab, while Group B received interventional therapy combined with lenvatinib. Disease remission rate, adverse reactions, liver function indicators, and tumor marker indicators were compared between the two groups. Results: The disease control rate (DCR) in Group A was higher than that in Group B (P < 0.05). There was no difference in adverse reaction rates between Group A and Group B (P > 0.05). Total bilirubin (TBil), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in Group A were lower than those in Group B (P < 0.05). Carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and alpha-L-fucosidase (AFU) levels in Group A were also lower than those in Group B (P < 0.05). Conclusion: Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels, lessened liver function damage, and a high disease control rate and treatment safety.

Study on the Efficacy and Quality of Life Impact of Combination Adjuvant Chemotherapy with Epirubicin and Docetaxel for Breast Cancer Patients after Radical Mastectomy

2025-05-29T15:41:54+08:00

Objective: To explore and analyze the clinical effect of combination adjuvant chemotherapy with epirubicin and docetaxel for patients after radical mastectomy for breast cancer. Methods: This study enrolled 60 patients between May 2022 and December 2024, who were randomly allocated into two equal treatment groups (n = 30 each). The control group received standard chemotherapy, whereas the observation group was treated with a combined adjuvant regimen of epirubicin and docetaxel. Therapeutic outcomes were systematically compared between the groups. Results: The comparative analysis of chemotherapy regimens revealed significant intergroup differences in multiple outcome measures. The observation group demonstrated superior clinical efficacy (96.67% vs 80.00%, P < 0.05) alongside a more favorable safety profile (adverse reaction incidence: 3.33% vs 20.00%, P < 0.05). Metabolic assessments showed better glycemic control in the observation group, with both fasting and postprandial blood glucose levels being significantly lower than controls (P < 0.05), while maintaining comparable values to pretreatment baselines (P > 0.05). Furthermore, quality of life assessments indicated significantly better outcomes in the observation group compared to controls (P < 0.05). Conclusion: The combination of epirubicin and docetaxel as adjuvant chemotherapy for patients after radical mastectomy for breast cancer has significant clinical effects, can improve patients’ quality of life, and has high safety. It is worthy of adoption.